Introduction
============

Endometrial cancer is a type of female malignant tumor with the highest incidence of all female cancers in developed countries ([@b1-ol-0-0-7590]). At present, the etiology of endometrial cancer remains unclear. The theory of 'estrogen without progesterone' (decrease in the level of progesterone before menopause that cannot antagonize estrogen, and an increase in the level of estrogen after menopause) posits that the occurrence of endometrial cancer is correlated with the disorder of estrogen and progesterone ([@b2-ol-0-0-7590]).

Clinical studies found that the incidence of endometrial cancer significantly increased after menopause without an increase in estrogen levels, indicating the existence of an estrogen-independent mechanism for the occurrence of endometrial cancer ([@b3-ol-0-0-7590]). The three major risk factors for endometrial cancer include obesity, diabetes and hypertension. All three factors share the common pathophysiological basis of insulin resistance and hyperinsulinemia ([@b4-ol-0-0-7590]). Insulin resistance and hyperinsulinemia can increase the risk of multiple malignancies, especially colorectal and endometrial cancer ([@b5-ol-0-0-7590]). Previous findings showed that the risk of endometrial cancer in patients with diabetes is double that of the normal population ([@b6-ol-0-0-7590]). Therefore, monitoring of indicators of glucose metabolism and insulin resistance index is of great significance for the assessment of the risk of endometrial cancer. The association between endometrial cancer and insulin resistance has become a focus of the studies on endometrial cancer. To the best of our knowledge, studies on the comparison of estrogen-dependent (typical) and estrogen-independent (atypical) endometrial cancer are relatively rare.

In the present study, the association between abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer was analyzed to explore the clinical significance of abnormal glucose metabolism and insulin resistance in early diagnosis, early treatment and the prevention of endometrial cancer.

Materials and methods
=====================

### Clinical data

A total of 65 endometrial cancer patients with complete clinical data were selected at the People\'s Hospital of Rizhao (Shandong, China) from June, 2010 to June, 2016. The patients were diagnosed by pathological examination. Inclusion criteria were: Patients with only primary tumor and without other malignancies, and patients who received no other treatments prior to surgery. The average age in the observation group was 56.3±14.2 years. Typical endometrial cancer (endometrioid adenocarcinoma) was observed in 52 cases and atypical endometrial cancer was observed in 13 cases; (6, adenosquamous carcinoma; 2, of mucinous adenocarcinoma; 2, of serous adenocarcinoma; 2, of clear cell carcinoma; and 1 case of undifferentiated carcinoma); 27, of diabetes; 38, showed no diabetes; 43, of menopause; and 22, of non-menopause. During the same period, 62 patients with endometrial benign lesions were selected as the control group. Patients with a history of cancer and the use of steroids were excluded. The average age of the control group was 57.1±13.7 years, and included 24 cases with diabetes, 38 without diabetes, 41 of menopause, and 21 of non-menopause. No significant differences in the average age, diabetes prevalence and proportion of menopause were found between groups (P\>0.05).

This study was approved by the Ethics Committee of People\'s Hospital of Rizhao. All the patients signed informed consent.

### Research methods

General clinical information including age, menstrual, marriage, disease (polycystic ovary syndrome, diabetes and hypertension) and family history, surgical methods, type of pathology, histological grade, estrogen receptor (ER) positive/negative, and progesterone receptor (PR) positive/negative were recorded.

The weight of fasted patients coated with single layer clothes was measured. Waist, abdominal and hip circumference were measured under smooth breathing. Shoes and hats were removed to measure height. All the indicators were measured twice to calculate the average value. Body mass index (BMI) was calculated as height/weight^2^; 24≤ BMI \<28 represents overweight, and BMI ≥28 represents obesity. The waist-to-hip ratio (WHR) was calculated as waist/hip circumference.

### Detection of serum markers

Venous blood (3--5 ml) was extracted through elbow vein from fasted patients in the morning, and transferred to an anticoagulant tube, followed by centrifugation at 3,000 g for 15 min to collect serum. Fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c) were detected using the glucose-oxidase method. Level of fasting insulin (FINS) was measured by electrochemiluminescence method. A level of FINS higher than the level of the control group + upper limit of 95% CI indicated an increase of FINS (hyperinsulinemia). Levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estrogen were measured by radioimmunoassay. Insulin resistance was assessed using homeostasis model assessment (HOMA) ([@b7-ol-0-0-7590]). Insulin resistance index (HOMA-IR) was calculated as (FPG mmol/l × FINS mU/l)/22.5 with values higher than that of control group HOMA-IR indicating insulin resistance ([@b8-ol-0-0-7590]).

### Statistical analysis

SPSS 20.0 software (IBM Corp., Armonk, NY, USA) was used for all the statistical analyses. Measurement data were expressed as mean ± SD, and comparison between groups were performed using t-test. Countable data were expressed as a percentage, and comparisons between groups were performed using the Fisher\'s exact test or Chi-square test. Logistic regression was performed for multi-factor analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Comparison of general information between the observation group (typical and atypical) and control groups

Significant differences in weight, BMI, waist circumference, abdominal circumference and WHR (P\<0.05), but not in height and hip circumference were found among the typical, atypical and control groups. The weight, BMI, waist and abdominal circumference were significantly higher in the typical than in the atypical and control groups. By contrast, no significant differences in those indicators were found between the atypical and control groups ([Table I](#tI-ol-0-0-7590){ref-type="table"}).

### Comparison of glucose metabolic index and sex hormone level between the observation (typical and atypical) and control groups

Significant differences in the levels of FINS, HOMA-IR, FSH and estrogen, but not in the levels of FBG, HbA1c and LH were found among the typical, atypical and control groups. Levels of FINS and HOMA-IR in the typical group were significantly higher than those in the atypical and control groups (P\<0.05). However, no significant differences were found between the atypical and control groups (P\>0.05). A significantly higher level of FSH and lower level of estrogen were found in the typical and atypical groups than in the control group (P\<0.05). With the level of FINS \>15.32 pmmol/l (level of control group + 95% CI upper limit) as a diagnostic criterion, increased FINS was found in 46 cases of the observation group, accounting for 70.77% (46/65), and 5 cases in the control group, accounting for 8.06% (5/62), with significant differences found between them (P\<0.05). With HOMA-IR \>2.29 as the diagnostic criterion (value of control group), insulin resistance was found in 52 cases of the observation group, accounting for 80.0% (52/65), and in 8 cases of the control group, accounting for 12.90%, with significant differences found between them (P\<0.05) ([Tables II](#tII-ol-0-0-7590){ref-type="table"} and [III](#tIII-ol-0-0-7590){ref-type="table"}).

### Comparison of glucose metabolic indexes between the diabetes and non-diabetes groups

Significant differences in the levels of FINS and HOMA-IR (P\<0.05), but not in the levels of FBG and HbA1c (P\>0.05), were found between the the observation and control groups in patients with or without diabetes ([Table IV](#tIV-ol-0-0-7590){ref-type="table"}).

### Comparison of levels of FINS and HOMA-IR in patients with different pathological features

No significant differences in the levels of FINS and HOMA-IR were found in patients with different pathological features (histopathological grade, FIGO stage, and ER and PR expression) (P\>0.05) ([Table V](#tV-ol-0-0-7590){ref-type="table"}).

### Multivariate logistic regression analysis

Multivariate logistic regression analysis revealed that HOMA-IR (OR=1.283), FINS (OR=1.240), estrogen (OR=1.192) and FSH (OR=1.002) were the risk factors for endometrial cancer. HOMA-IR showed the strongest correlation with endometrial carcinoma, followed by FINS, estrogen and FSH. A lower level of FSH indicated, a higher risk of endometrial cancer ([Table VI](#tVI-ol-0-0-7590){ref-type="table"}).

Discussion
==========

According to different pathogenesis, Bristow believed that endometrial cancer can be divided into the estrogen-dependent and -independent clinicopathological types ([@b9-ol-0-0-7590]).

Type I is estrogen-dependent endometrial cancer, and the occurrence of type I is likely caused by the effects of estrogen with the antagonist of progesterone in endometrium. Type I accounts for 80--90% of endometrial cancer, and the histopathologic types are adenocarcinoma. Type I mainly affects young patients, especially ones combined with metabolic syndrome (obesity, hypertension, diabetes), infertility, delayed menopause, and a family history of endometrial cancer. Patients with type I endometrial cancer usually present as PR-positive and have a favorable prognosis ([@b10-ol-0-0-7590]). In the present study, type I endometrial cancer accounted for 80.0% (52/65) of all the cases, which is consistent with previous studies ([@b11-ol-0-0-7590]). Type II is estrogen-independent endometrial cancer. In type II, atrophic endometrium can be observed around lesions. Occurrence of this type shows no correlation with estrogen, but is closely correlated with mutations in p53, inactivation of E-cadherin and overexpression of Her2/neu ([@b12-ol-0-0-7590]). Type II is relatively rare, and histopathological types mainly include mucinous adenocarcinoma, serous adenocarcinoma, clear cell carcinoma and other non-uterine-like adenocarcinoma. Type II endometrial cancer mainly affects elderly thin women. Tumor differentiation is usually poor and PR is usually negative. Patients with type II endometrial cancer usually show a high degree of malignancy and poor prognosis ([@b13-ol-0-0-7590]).

Previous findings have shown that obesity is the primary risk factor for endometrial cancer, and weight 13.5 and 22.5 kg higher than the ideal value can increase the risk of endometrial cancer by 3- and 10-fold, respectively ([@b14-ol-0-0-7590]).

BMI is another indicator of obesity. Findings have shown that patients with a higher BMI usually have a higher risk of endometrial cancer ([@b15-ol-0-0-7590]). In the present study, WHR was significantly higher in the typical than in the control group (P\<0.05), which is consistent with previous findings showing that patients with upper body obesity have a higher risk of endometrial cancer compared to patients with other types of obesity ([@b16-ol-0-0-7590]). Type 2 diabetes is another risk factor for endometrial cancer. It has been shown that, serum insulin levels can increase the incidence of endometrial cancer in a dose-dependent manner. Additionally, hyperinsulinemia is considered to be an independent risk factor for the incidence of endometrial cancer ([@b17-ol-0-0-7590]). Type 2 diabetes, not only increases the incidence of EC ([@b18-ol-0-0-7590]), but also increases the relative risk of death in EC patients ([@b19-ol-0-0-7590]). Type 2 diabetes combined with obesity can significantly increase the risk of EC ([@b20-ol-0-0-7590],[@b21-ol-0-0-7590]). In the present study, the levels of FINS and HOMA-IR were significantly higher in the typical group than in the atypical and control groups (P\<0.05). The incidence of hyperinsulinemia and insulin resistance was also significantly higher in the observation group than that in the control group (P\<0.05). Insulin resistance is not a disease, but the key pathophysiological process of obesity, diabetes, hypertension and even metabolic syndrome. Poor lifestyle is the leading cause of obesity, diabetes and other insulin resistance. Modified diet structure and appropriate physical exercise is imperative in preventing obesity, diabetes and other diseases, but can also effectively prevent endometrial cancer.

Insulin resistance is defined as the reduced biological effect of a certain amount of insulin after binding to the receptor. Insulin resistance is manifested by the decreased use and increased output of peripheral glucose ([@b22-ol-0-0-7590]). At the early stage of insulin resistance, pancreatic β-cells will secrete excessive insulin to induce hyperinsulinemia. With the exhaustion of β-cells, blood glucose levels continue to rise, ultimately leading to the development of diabetes ([@b23-ol-0-0-7590]). In the present study, the incidence of hyperinsulinemia in the observation group was 70.77%, which is significantly higher than that of the control group (8.06%). According to the HOMA-IR evaluation method, 80.0% of patients in the observation group had insulin resistance, which was significantly higher than that of the control group. With the improvement of insulin resistance or metabolic abnormalities, the risk of endometrial cancer can also be reduced ([@b24-ol-0-0-7590]). However, the mechanism of the role of insulin in endometrial cancer remains unclear.

The possible mechanisms involved the fact that, insulin can bind to insulin or vascular endothelial growth factor receptor in endometrial cells to promote cell proliferation, inhibit apoptosis, induce the expression of vascular endothelial growth factor, and promote angiogenesis, which in turn leads to the occurrence of endometrial cancer. Additionally insulin is involved in tumor development by directly or indirectly affecting endogenous estrogen metabolism ([@b25-ol-0-0-7590]). Under physiological conditions, 30--50% of estrogen in the plasma can bind to the sex hormone-binding globulin (SHBG) to form an inactive form, while high insulin can inhibit the secretion of SHBG to increase free active estrogen in blood circulation ([@b26-ol-0-0-7590]). In addition, high insulin can affect the expression of adipose tissue aromatase P450c17 in ovarian and adrenal gland, promote androgen synthesis, and increase estrogen peripheral transformation ([@b27-ol-0-0-7590]). Insulin can also promote the expression of endometrial ER, which in turn enhances the function of estrogen ([@b28-ol-0-0-7590]). Insulin can continue to the proliferation of endometrial cells under the effects of estrogen, thereby increasing the incidence of endometrial cancer ([@b29-ol-0-0-7590]).

The results of the present study have shown that HOMA-IR (OR=1.283), FINS (OR=1.240), estrogen (OR=1.192) and FSH (OR=1.002) were risk factors for endometrial cancer. Of these, HOMA-IR was strongly correlated with endometrial carcinoma, followed by FINS, estrogen and FSH. Higher levels of HOMA-IR, FINS and estrogen, and lower levels of FSH can increase the risk of endometrial cancer. Insulin may also be involved in the development of endometrium by affecting the levels of sex hormone. Multi-center studies with large sample size should be performed to detect the abovementioned indicators to block high-risk factors of endometrial cancer ([@b30-ol-0-0-7590]), in order to achieve the early prevention and treatment of endometrial cancer.

###### 

Comparison of general information among the typical, atypical and control groups (mean ± SD).

                                 Groups                                                                                                                                     
  ------------------------------ ------------- --------------------------------------------------------- ---------------------------------------------------------- ------- -------
  Height (m)                     1.61±0.04     1.60±0.05                                                 1.60±0.03                                                  0.358   0.714
  Weight (kg)                    70.22±8.17    63.14±9.32^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^   62.76±8.53^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^    5.865   0.003
  BMI (kg/m^2^)                  27.58±2.64    24.23±2.97^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^   24.18±3.21^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^    7.697   0.002
  Waist circumference (cm)       98.03±7.89    92.06±9.24^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^   91.69±10.30^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^   3.932   0.009
  Abdominal circumference (cm)   102.78±5.46   96.18±4.68^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^   95.98±5.17^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^    3.251   0.032
  Hip circumference (cm)         99.04±5.87    96.14±5.28                                                96.02±5.62                                                 1.423   0.316
  WHR                            0.984±0.05    0.945±0.04^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^   0.942±0.06^[a](#tfn1-ol-0-0-7590){ref-type="table-fn"}^    4.684   0.007

Compared with typical group, P\<0.05; BMI, body mass index; WHR, waist-to-hip ratio; SD, standard deviation.

###### 

Comparison of glucose metabolic index and sex hormone level among the typical, atypical and control groups (mean ± SD).

                   Groups                                                                                                                                                                                   
  ---------------- -------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------- -------
  FBG (mmol/l)     5.21±0.34      5.15±0.33                                                 5.13±0.35                                                                                               0.485   0.641
  HbA1c (%)        5.87±0.56      5.68±0.51                                                 5.64±0.49                                                                                               0.865   0.073
  FINS (pmmol/l)   18.45±5.32     10.23±3.47^[a](#tfn2-ol-0-0-7590){ref-type="table-fn"}^   10.18±3.21^[a](#tfn2-ol-0-0-7590){ref-type="table-fn"}^                                                 7.967   0.003
  HOMA-IR          3.93±1.19      2.36±1.06^[a](#tfn2-ol-0-0-7590){ref-type="table-fn"}^    2.29±1.02^[a](#tfn2-ol-0-0-7590){ref-type="table-fn"}^                                                  3.932   0.008
  FSH (mIU/ml)     37.84±9.65     36.47±9.65                                                50.21±9.76^[a](#tfn2-ol-0-0-7590){ref-type="table-fn"},[b](#tfn3-ol-0-0-7590){ref-type="table-fn"}^     8.215   0.002
  LH (mIU/ml)      29.12±10.07    29.65±10.28                                               30.13±10.62                                                                                             0.634   0.516
  E2 (pg/ml)       472.32±56.25   462.32±55.76                                              367.61±55.43^[a](#tfn2-ol-0-0-7590){ref-type="table-fn"},[b](#tfn3-ol-0-0-7590){ref-type="table-fn"}^   4.864   0.006

Compared with typical group, P\<0.05

compared with atypical group, P\<0.05; FBG, fasting blood glucose glucose; HbA1c, glycosylated hemoglobin; FINS, fasting insulin level; HOMA-IR, insulin resistance index; FSH, follicle estrogen; LH, luteinizing hormone; SD, standard deviation.

###### 

Comparison of incidence of hyperinsulinemia and insulin resistance between observation group and control group (cases, %).

            Groups                                  
  --------- --------------- --------------- ------- -------
  FINS      70.77 (46/65)   8.06 (5/62)     7.653   0.001
  HOMA-IR   80.0 (52/65)    12.90% (8/62)   5.346   0.002

FINS, fasting insulin level; HOMA-IR, insulin resistance index.

###### 

Comparison of glucose metabolic indexes between diabetes and non-diabetes group (mean ± SD).

                   Groups                                                                              
  ---------------- ------------ --------------------------------------------------------- ------------ --------------------------------------------------------
  FBG (mmol/l)     5.56±1.51    5.53±1.43                                                 4.95±1.12    4.87±1.09
  HbA1c (%)        6.39±0.46    6.33±0.52                                                 5.76±0.57    5.71±0.53
  FINS (pmmol/l)   21.05±5.47   12.93±4.86^[a](#tfn5-ol-0-0-7590){ref-type="table-fn"}^   17.02±6.54   9.13±3.62^[a](#tfn5-ol-0-0-7590){ref-type="table-fn"}^
  HOMA-IR          4.48±1.12    2.89±1.03^[a](#tfn5-ol-0-0-7590){ref-type="table-fn"}^    3.45±1.13    1.98±0.92^[a](#tfn5-ol-0-0-7590){ref-type="table-fn"}^

Compared with control group, P\<0.05; FBG, fasting blood glucose glucose; HbA1c, glycosylated hemoglobin; FINS, fasting insulin level; HOMA-IR, insulin resistance index; SD, standard deviation.

###### 

Comparison of levels of FINS and HOMA-IR among patients with different pathological features (mean ± SD).

  Pathological features   n    FINS (pmmol/l)   χ^2^ value   P-value   HOMA-IR     χ^2^ value   P-value
  ----------------------- ---- ---------------- ------------ --------- ----------- ------------ ---------
  Pathological grades                           2.65         0.094                 2.17         0.011
    G1                    23   20.01±6.52                              3.93±1.79                
    G2                    28   17.32±6.43                              3.82±1.85                
    G3                    14   18.24±5.96                              3.74±1.91                
  FIGO stage                                    5.87         0.059                 4.78         0.062
    I--II                 56   17.85±6.14                              3.83±1.87                
    III--IV               9    13.26±5.98                              3.54±1.96                
  PR                                            3.54         0.083                 3.87         0.078
    Positive              52   18.61±5.96                              3.84±1.58                
    Negative              13   16.23±6.05                              3.69±1.84                
  ER                                            4.12         0.075                 4.32         0.069
    Positvie              51   18.78±6.27                              3.85±1.82                
    Negative              14   16.06±5.83                              3.66±1.70                

FIGO, International Federation of Gynecology and Obstetrics; PR, progesterone receptor; ER, estrogen receptor; SD, standard deviation.

###### 

Multivariate logistic regression analysis.

  Factors   b value   Wald χ^2^ value   P-value   OR (95% confidence interval)
  --------- --------- ----------------- --------- ------------------------------
  FINS      0.775     7.324             0.003     1.240 (1.085--1.461)
  HOMA-IR   0.386     8.642             0.000     1.283 (1.096--1.567)
  FSH       −0.674    5.813             0.025     1.002 (0.942--1.012)
  E2        0.873     6.701             0.013     1.192 (1.083--1.386)

FINS, fasting insulin level; HOMA-IR, insulin resistance index; FSH, follicle estrogen.
